Mizuho Initiates Coverage on Regenxbio (RGNX)

Mizuho began coverage on shares of Regenxbio (NASDAQ:RGNX) in a note issued to investors on Monday. The firm set a “neutral” rating and a $28.00 price target on the biotechnology company’s stock. Mizuho’s price target would suggest a potential upside of 4.67% from the stock’s current price.

Several other equities analysts have also weighed in on the stock. BidaskClub upgraded shares of Regenxbio from a “hold” rating to a “buy” rating in a report on Saturday. Raymond James Financial restated a “buy” rating on shares of Regenxbio in a report on Friday, January 5th. Chardan Capital restated a “buy” rating on shares of Regenxbio in a report on Monday, December 11th. TheStreet lowered shares of Regenxbio from a “c” rating to a “d+” rating in a report on Tuesday, November 28th. Finally, Barclays began coverage on shares of Regenxbio in a report on Wednesday, November 22nd. They issued an “overweight” rating and a $38.00 target price on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $40.63.

Shares of Regenxbio (NASDAQ RGNX) traded up $1.05 during midday trading on Monday, hitting $26.75. 223,916 shares of the stock traded hands, compared to its average volume of 464,156. Regenxbio has a 52-week low of $16.30 and a 52-week high of $36.45. The firm has a market capitalization of $800.43, a price-to-earnings ratio of -9.91 and a beta of -1.30.

In related news, SVP Curran Simpson sold 30,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $33.03, for a total value of $990,900.00. Following the sale, the senior vice president now owns 69,500 shares in the company, valued at approximately $2,295,585. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $27.33, for a total transaction of $273,300.00. Following the completion of the sale, the insider now owns 248,530 shares in the company, valued at approximately $6,792,324.90. The disclosure for this sale can be found here. Insiders sold a total of 94,000 shares of company stock worth $2,879,096 in the last 90 days. 17.00% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the business. Sphera Funds Management LTD. purchased a new stake in Regenxbio in the 4th quarter valued at about $735,000. Citadel Advisors LLC increased its stake in Regenxbio by 62.2% in the 4th quarter. Citadel Advisors LLC now owns 987,752 shares of the biotechnology company’s stock valued at $32,843,000 after buying an additional 378,612 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in Regenxbio in the 4th quarter valued at about $407,000. Artal Group S.A. increased its stake in Regenxbio by 56.3% in the 4th quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $8,313,000 after buying an additional 90,000 shares during the last quarter. Finally, Royce & Associates LP purchased a new stake in Regenxbio in the 4th quarter valued at about $1,962,000. Hedge funds and other institutional investors own 68.66% of the company’s stock.

WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/12/mizuho-initiates-coverage-on-regenxbio-rgnx.html.

Regenxbio Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply